StockNews.com started coverage on shares of Global Cord Blood (NYSE:CO – Get Rating) in a report issued on Thursday. The brokerage set a “strong-buy” rating on the medical research company’s stock.
Global Cord Blood stock opened at $2.34 on Thursday. The company has a market cap of $284.43 million, a price-to-earnings ratio of 3.55 and a beta of 0.39. The business’s 50 day simple moving average is $3.34 and its 200 day simple moving average is $3.88. Global Cord Blood has a 12 month low of $2.10 and a 12 month high of $6.31.
Global Cord Blood (NYSE:CO – Get Rating) last posted its quarterly earnings results on Monday, February 28th. The medical research company reported $0.17 earnings per share (EPS) for the quarter. The business had revenue of $49.78 million during the quarter. Global Cord Blood had a net margin of 41.98% and a return on equity of 11.42%.
Global Cord Blood Company Profile (Get Rating)
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.
Featured Articles
- Get a free copy of the StockNews.com research report on Global Cord Blood (CO)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- It’s Time to Buy into Planet Fitness Stock
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.